In cancer cells, the ability of metformin to alter cancer metabolism and mitochondrial function and to modulate intracellular signaling activity related to key oncogenic pathways such as the Ras/Raf/MEK/ERK, PI3K/Akt, and mTOR pathways, retards cancer cell growth, proliferation, migration, increases cell death, and inhibits EMT, invasion, and metastasis [36,43,44,45,46,47]. Here, RAF1 is linked to cancer.